* history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease * history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection * history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members * history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood * known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test (non-booster arms only) * any history of malignant disease ≤5 years prior to registration * history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia

* history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease * history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection * history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members * history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood * known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test (non-booster arms only) * any history of malignant disease ≤5 years prior to registration * history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia

history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test (non-booster arms only) any history of malignant disease ≤5 years prior to registration history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia

history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test (non-booster arms only) any history of malignant disease ≤5 years prior to registration history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia

- history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease - history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection - history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members - history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood - known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test - any history of malignant disease ≤5 years prior to registration - history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia

- history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease - history of chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior to screening) or ongoing respiratory tract infection - history of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any coagulation dysregulation disorder, or a history of thrombosis noted in immediate family members - history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood - known previous infection with sars-cov-2 or presence of antibodies against sars-cov-2 or a positive sars-cov-2 pcr test - any history of malignant disease ≤5 years prior to registration - history of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia